APO-QUININE 300mg
Natural health product licensed in Canada
- Licence holder
- Apotex Inc.
- NPN or DIN-HM
- 02254522
- Status
- Inactive licence
- Licence date
- 20 August 2008
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- DIN de transition
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
Medicinal composition not provided.
Non-medicinal ingredients
Talc, cellulose, Silicon dioxide colloïdal, Stéarate de magnésium, Gélatine
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Enfants | Not specified | minimum: 1 Capsule ; maximum: 3 Capsule | 3 Tous les jours |
| Adultes | Not specified | 3 Capsule | 3 Tous les jours |
Uses authorised in Canada
Antimalarial
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
Quinine has quinidine-like activity; the same precautions should be taken with quinine as with quinidine in patients with atrial fibrillation. Advise patients to notify physician if cutaneous angiodematous, visual or auditory symptoms occur. If evidence of hemolysis appears, stop the drug immediately.
- Contre-indications
Quinine is contraindicated in patients who have a known hypersensitivity to the drug. Cross-sensitivity between quinine and quinidine may occur. Quinine should not be used in patients with G-6-PD deficiency; tinnitus; optic neuritis; myasthenia gravis (quinine may exacerbate muscle weakness due to its neuromuscular blocking effects); hypoglycaemia; pregnancy unless required to treat a severe, life-threatening chloroquine-resistant malaria infection in the mother; history of blackwater fever and thrombocytopenic purpura (associated with previous quinine ingestion.)
Source
Official Health Canada record, licence 02254522
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.